Growth Metrics

Disc Medicine (IRON) Debt to Equity (2020 - 2022)

Disc Medicine (IRON) reported Debt to Equity of -$0.04 for Q2 2022, down 170.33% year-over-year from $0.05 in Q2 2021, and up 37.67% on a QoQ basis from -$0.06 in Q1 2022.

Disc Medicine (IRON) has 3 years of Debt to Equity data on file, last reported at -$0.04 in Q2 2022.

  • Quarterly Debt to Equity fell 170.33% year-over-year to -$0.04 in Q2 2022, while the trailing twelve-month figure through Jun 2022 was -$0.04 (down 170.33% YoY) and the FY2021 annual result came in at -$0.11, up 69.09% from the prior year.
  • Debt to Equity rose to -$0.04 in Q2 2022 per IRON's latest filing, from -$0.06 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.05 in Q1 2021 and bottomed at -$0.35 in Q4 2020.
  • The 3-year median for Debt to Equity is -$0.04 (2022), against an average of -$0.06.
  • The widest annual swing landed in 2021, when Debt to Equity soared 69.09%; it then plunged 205.85% in 2022.
  • Tracing IRON's Debt to Equity over 3 years: stood at -$0.35 in 2020, then soared by 69.09% to -$0.11 in 2021, then surged by 67.04% to -$0.04 in 2022.
  • Per Business Quant, the three latest IRON Debt to Equity figures stand at -$0.04 (Q2 2022), -$0.06 (Q1 2022), and -$0.11 (Q4 2021).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt/Equity (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 0.06
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Disc Medicine 2.76 Bn 2.03 Bn - -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2022 -0.04
Mar 31, 2022 -0.06
Dec 31, 2021 -0.11
Sep 30, 2021 0.05
Jun 30, 2021 0.05
Mar 31, 2021 0.05
Dec 31, 2020 -0.35